Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
AVBP
AVBP
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AVBP News
Aarvik to Present Novel ADCs at AACR Annual Meeting 2026
Mar 17 2026
Newsfilter
Surge in Options Trading Volume for Alphabet and ArriVent
Mar 06 2026
NASDAQ.COM
Growth Prospects for the EGFR-NSCLC Market Analyzed
Feb 11 2026
Newsfilter
FDA Accelerates Oncology Drug Approvals, Boosting Market Potential
Feb 05 2026
Newsfilter
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
PRnewswire
Oncolytics Biotech Advances Pelareorep for Anal Cancer with 29% Response Rate
Jan 12 2026
Newsfilter
Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer
Dec 16 2025
Newsfilter
Oncolytics Biotech Achieves 33% Response Rate in KRAS-Mutant Colorectal Cancer
Dec 16 2025
PRnewswire
Top Analysts Recommend 3 Best Stocks to Purchase Now, 9/10/2025
Sep 10 2025
TipRanks
Arrivent Unveils Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Lung Cancer Conference
Sep 09 2025
Newsfilter
Citigroup Maintains Buy on ArriVent BioPharma, Lowers Price Target to $33
Aug 12 2025
Benzinga
New Strong Sell Stocks for July 21st
Jul 21 2025
NASDAQ.COM
ArriVent BioPharma prices $75M equity offering
Jul 02 2025
SeekingAlpha
ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Jul 02 2025
Yahoo Finance
Clear Street Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $32
Jun 25 2025
Benzinga
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
Jun 20 2025
Newsfilter
Show More News
